Breast cancer prognostic classification in the molecular era: The role of histological grade

Breast Cancer Research

Volumn 12, Issue 4, 2010, Pages

  Rakha, Emad A ^a   Reis Filho, Jorge S ^b   Baehner, Frederick ^c   Dabbs, David J ^d   Decker, Thomas ^e   Eusebi, Vincenzo ^f   Fox, Stephen B ^g   Ichihara, Shu ^h   Jacquemier, Jocelyne ⁱ   Lakhani, Sunil R ^j   Palacios, José ^k   Richardson, Andrea L ^l   Schnitt, Stuart J ^m   Schmitt, Fernando C ⁿ   Tan, Puay Hoon ^o   Tse, Gary M ^p   Badve, Sunil ^q   Ellis, Ian O ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f BELLARIA HOSPITAL   (Italy)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

ⁱ INSTITUT PAOLI CALMETTES   (France)

^j UNIVERSITY OF QUEENSLAND   (Australia)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ University of Porto   (Portugal)

^o SINGAPORE GENERAL HOSPITAL   (Singapore)

^p CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^q INDIANA UNIVERSITY HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL PRACTICE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; MICROARRAY ANALYSIS; MORPHOLOGY; PATIENT DECISION MAKING; PROGNOSIS; REPRODUCIBILITY; REVIEW; VALIDITY; BREAST TUMOR; CLASSIFICATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HOSPITALIZATION; LYMPH NODE; PATHOLOGY; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TUMOR BURDEN;

EID: 78649992702     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2607     Document Type: Review

References (81)

1. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
2. Pathology Reporting of Breast Disease: A Joint Document Incorporating the Third Edition of the NHS Breast Screening Programme's Guidelines for Pathology Reporting in Breast Cancer Screening and the Second Edition of The Royal College of Pathologists' Minimum Dataset for Breast Cancer Histopathology 2005, Sheffield; NHS Cancer Screening Programmes and The Royal College of Pathologists.
3. Tavassoli FA, Devilee P. World Health Organization classification of tumours. Pathology and Genetics Tumours of the Breast and Female Genital Organs 2003, 19-23. Lyon: IARC Press.
4. Sundquist M, Thorstenson S, Brudin L, Nordenskjold B. Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat 1999, 53:1-8. 10.1023/A:1006052115874, 10206067.
5. Saimura M, Fukutomi T, Tsuda H, Sato H, Miyamoto K, Akashi-Tanaka S, Nanasawa T. Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor. J Surg Oncol 1999, 71:101-105. 10.1002/(SICI)1096-9098(199906)71:2<101::AID-JSO8>3.0.CO;2-G, 10389866.
6. Lundin J, Lundin M, Holli K, Kataja V, Elomaa L, Pylkkanen L, Turpeenniemi- Hujanen T, Joensuu H. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol 2001, 19:28-36.
7. Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, Page DL, Robert NJ. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 2000, 18:2059-2069.
8. Anderson TJ, Alexander FE, Lamb J, Smith A, Forrest AP. Pathology characteristics that optimize outcome prediction of a breast screening trial. Br J Cancer 2000, 83:487-492. 2374653, 10945496, 10.1054/bjoc.2000.1286.
9. Frkovic-Grazio S, Bracko M. Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma. J Clin Pathol 2002, 55:88-92. 1769590, 11865000.
10. Warwick J, Tabar L, Vitak B, Duff y SW. Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study. Cancer 2004, 100:1331-1336. 10.1002/cncr.20140, 15042664.
11. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW, Ellis IO. Prognostic significance of nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008, 26:3153-3158. 10.1200/JCO.2007.15.5986, 18490649.
12. Blamey RW, Hornmark-Stenstam B, Ball G, Blichert-Toft M, Cataliotti L, Fourquet A, Gee J, Holli K, Jakesz R, Kerin M, Mansel R, Nicholson R, Pienkowski T, Pinder S, Sundquist M, van de Vijver M, Ellis I. ONCOPOOL- A European database for 16,944 cases of breast cancer. Eur J Cancer 2010, 46:56. 10.1016/j.ejca.2009.09.009, 19811907.
13. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002, 235:10-26. 1422391, 11753038, 10.1097/00000658-200201000-00003.
14. Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991, 68:2142-2149. 10.1002/1097-0142(19911115)68:10<2142::AID-CNCR2820681010>3.0.CO;2-D, 1913453.
15. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219. 10.1007/BF01840834, 1391987.
16. Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, Armstrong N, van't Veer LJ, Ravdin PM. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 2009, 10:1070-1076. 10.1016/S1470-2045(09)70254-2, 19801202.
17. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329. 2720818, 19535820, 10.1093/annonc/mdp322.
18. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Borresen- Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 166244, 12829800, 10.1073/pnas.0932692100.
19. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398. 193572, 12917485, 10.1073/pnas.1732912100.
20. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541. 10.1016/j.ccr.2006.10.009, 17157792.
21. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 2008, 26:1-10. 10.1080/07357900701784238, 18181038.
22. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
23. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734. 10.1200/JCO.2005.04.7985, 16720680.
24. Correa Geyer F, Reis-Filho JS. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?. Int J Surg Pathol 2009, 17:285-302. 10.1177/1066896908328577, 19103611.
25. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010, 220:263-280. 10.1002/path.2629, 19927298.
26. Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess 2006, 10:iii-iv, ix-xi, 1-204.
27. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, Robertson JF, Ellis IO. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995, 27:219-226. 10.1111/j.1365-2559.1995.tb00213.x, 8522285.
28. Assessment of breast cancer grading using the Nottingham combined histological grading system. , http://www.nottingham.ac.uk/~mrzarg/nott.htm
29. Walker RA. Prognostic and Predictive Factors in Breast Cancer 2003, New York: Informa Health Care, 1.
30. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, Delorenzi M. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65. 2575538, 18662380, 10.1186/bcr2124.
31. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008, 100:1380-1388. 2556704, 18812550, 10.1093/jnci/djn309.
32. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 2000, 88:804-813. 10.1002/(SICI)1097-0142(20000215)88:4<804::AID-CNCR11>3.0.CO;2-Y, 10679650.
33. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008, 14:5158-5165. 10.1158/1078-0432.CCR-07-4756, 18698033.
34. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007, 25:4772-4778. 10.1200/JCO.2007.12.2747, 17876012.
35. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO. Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. Eur J Cancer 2008, 44:73-83. 10.1016/j.ejca.2007.10.009, 18035533.
36. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002, 20:3628-3636. 10.1200/JCO.2002.02.026, 12202663.
37. Pedersen L, Zedeler K, Holck S, Schiodt T, Mouridsen HT. Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer 1995, 31A:2289-2295. 10.1016/0959-8049(95)00408-4, 8652258.
38. Rakha EA, El-Sayed ME, Reed J, Lee AH, Evans AJ, Ellis IO. Screen-detected breast lesions with malignant needle core biopsy diagnoses and no malignancy identified in subsequent surgical excision specimens (potential false-positive diagnosis). Eur J Cancer 2009, 45:1162-1167. 10.1016/j.ejca.2008.12.002, 19121932.
39. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124:966-978.
40. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual 2010, New York: Springer, 7.
41. Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol 2006, 24:2113-2122. 10.1200/JCO.2005.02.8035, 16648513.
42. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 2000, 191:1-6. discussion 6-8, 10.1016/S1072-7515(00)00310-0, 10898177.
43. Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson JF, Blamey RW. The prognosis of small primary breast cancers. Eur J Cancer 1999, 35:908-912. 10.1016/S0959-8049(99)00056-8, 10533470.
44. Rakha EA, Lee AH, Evans AJ, Menon S, Assad NY, Hodi Z, Macmillan D, Blamey RW, Ellis IO. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol 2010, 28:99-104. 10.1200/JCO.2009.23.5051, 19917872.
45. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569. 10.1056/NEJMoa052933, 16899776.
46. Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AH, Ellis IO. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 2008, 111:121-127. 10.1007/s10549-007-9768-4, 17929165.
47. Denley H, Pinder SE, Elston CW, Lee AH, Ellis IO. Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 2001, 54:20-24. 1731277, 11271783, 10.1136/jcp.54.1.20.
48. Rakha EA, Ellis IO. An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J Clin Pathol 2007, 60:1300-1306. 10.1136/jcp.2006.045377, 17630399.
49. Amat S, Penault-Llorca F, Cure H, Le Bouedec G, Achard JL, Van Praagh I, Feillel V, Mouret-Reynier MA, Dauplat J, Chollet P. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002, 20:791-796.
50. Frierson HF, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, Boyd JC, Wilbur DC. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995, 103:195-198.
51. Ellis IO, Coleman D, Wells C, Kodikara S, Paish EM, Moss S, Al-Sam S, Anderson N, Bobrow L, Buley I, Connolly CE, Dallimore NS, Hales S, Hanby A, Humphreys S, Knox F, Lowe J, Macartney J, Nash R, Parham D, Patnick J, Pinder SE, Quinn CM, Robertson AJ, Shrimankar J, Walker RA, Winder R. Impact of a national external quality assessment scheme for breast pathology in the UK. J Clin Pathol 2006, 59:138-145. 1860326, 16443727, 10.1136/jcp.2004.025551.
52. Theissig F, Kunze KD, Haroske G, Meyer W. Histological grading of breast cancer. Interobserver, reproducibility and prognostic significance. Pathol Res Pract 1990, 186:732-736.
53. Jacquemier J, Charpin C. [Reproducibility of histoprognostic grades of invasive breast cancer]. Ann Pathol 1998, 18:385-390.
54. Chowdhury N, Pai MR, Lobo FD, Kini H, Varghese R. Interobserver variation in breast cancer grading: a statistical modeling approach. Anal Quant Cytol Histol 2006, 28:213-218.
55. Page DL, Gray R, Allred DC, Dressler LG, Hatfield AK, Martino S, Robert NJ, Wood WC. Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192). Am J Clin Oncol 2001, 24:10-18. 10.1097/00000421-200102000-00002, 11232942.
56. Longacre TA, Ennis M, Quenneville LA, Bane AL, Bleiweiss IJ, Carter BA, Catelano E, Hendrickson MR, Hibshoosh H, Layfield LJ, Memeo L, Wu H, O'malley FP. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol 2006, 19:195-207. 10.1038/modpathol.3800496, 16341153.
57. Boiesen P, Bendahl PO, Anagnostaki L, Domanski H, Holm E, Idvall I, Johansson S, Ljungberg O, Ringberg A, Ostberg G, Fernö M. Histologic grading in breast cancer--reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. Acta Oncol 2000, 39:41-45. 10.1080/028418600430950, 10752652.
58. Sikka M, Agarwal S, Bhatia A. Interobserver agreement of the Nottingham histologic grading scheme for infiltrating duct carcinoma breast. Indian J Cancer 1999, 36:149-153.
59. Hopton DS, Thorogood J, Clayden AD, MacKinnon D. Observer variation in histological grading of breast cancer. Eur J Surg Oncol 1989, 15:21-23.
60. European Commission European Guidelines for Quality Assurance in Mammography Screening 1996, Luxembourg: Office for Official Publications of the European Communities, European Commission.
61. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I, Elston C. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995, 26:873-879. 10.1016/0046-8177(95)90010-1, 7635449.
62. Pathology and genetics of tumors of the breast and female genital organs. World Health Organization Classification of Tumors 2003, Lyon: IACR Press, Tavassoli FA, Devilee P.
63. Lusa L, McShane LM, Reid JF, De Cecco L, Ambrogi F, Biganzoli E, Gariboldi M, Pierotti MA. Challenges in projecting clustering results across gene expression-profiling datasets. J Natl Cancer Inst 2007, 99:1715-1723. 10.1093/jnci/djm216, 18000217.
64. Nuyten DS, Chang HY, Brown PO, Van de Vijver MJ. Reproducibility of molecular portraits in early stage breast cancer. Breast Cancer Research 2005, 7(Suppl 2):P4.
65. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005, 102:3738-3743. 548329, 15701700, 10.1073/pnas.0409462102.
66. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-272. 10.1093/jnci/djj052, 16478745.
67. Natrajan R, Lambros MB, Geyer FC, Marchio C, Tan DS, Vatcheva R, Shiu KK, Hungermann D, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Buerger H, Reis-Filho JS. Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. Genes Chromosomes Cancer 2009, 48:351-365. 10.1002/gcc.20646, 19156836.
68. Yu K, Lee CH, Tan PH, Hong GS, Wee SB, Wong CY, Tan P. A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res 2004, 64:2962-2968. 10.1158/0008-5472.CAN-03-2430, 15126326.
69. Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 2008, 108:191-201. 10.1007/s10549-007-9596-6, 18297396.
70. Dunkler D, Michiels S, Schemper M. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis?. Eur J Cancer 2007, 43:745-751. 10.1016/j.ejca.2006.11.018, 17257824.
71. Eden P, Ritz C, Rose C, Ferno M, Peterson C. 'Good Old' clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 2004, 40:1837-1841. 10.1016/j.ejca.2004.02.025, 15288284.
72. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
73. Bueno-de-Mesquita JM, Sonke GS, van de Vijver MJ, Linn SC. Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. Ann Oncol 2009,
74. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005, 11:313-324.
75. Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ, Haybittle JL. Reading the prognosis of the individual with breast cancer. Eur J Cancer 2007, 43:1545-1547. 10.1016/j.ejca.2007.01.003, 17320376.
76. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005, 116:340-350. 10.1002/ijc.21004, 15818618.
77. Elston CW. The assessment of histological differentiation in breast cancer. Aust N Z J Surg 1984, 54:11-15. 10.1111/j.1445-2197.1984.tb06677.x, 6586161.
78. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, Golouh R, Save-Soderbergh J, Holloway L, Russell I, Rudenstam CM. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 1986, 58:2662-2670. 10.1002/1097-0142(19861215)58:12<2662::AID-CNCR2820581219>3.0.CO;2-Y, 3536070.
79. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989, 64:1914-1921. 10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G, 2551477.
80. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 1994, 32:281-290. 10.1007/BF00666005, 7865856.
81. Thomas JS, Kerr GR, Jack WJ, Campbell F, McKay L, Pedersen HC, Kunkler IH, Cameron DA, Chetty U, Bartlett JM. Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-up. Histopathology 2009, 55:724-731. 10.1111/j.1365-2559.2009.03429.x, 19845790.